短程大剂量米托蒽醌和阿糖胞苷治疗难治性和复发的急性白血病(英文)  

Short Course High Dose Mitoxantrone with Cytarabine for Treatment of Refractory and Relapsed Acute Leukemia

作　　者：王恒湘[1] 薛梅[1] 朱玲[1] 阎洪敏[1] 纪树荃[1] 

机构地区：[1]北京空军总医院血液科,北京100036

出　　处：《中国实验血液学杂志》2001年第1期70-72,共3页Journal of Experimental Hematology

摘　　要：初诊的急性白血病 ,化疗常可获得较高的缓解率 ,而难治性和复发的白血病治疗效果较差。本研究观察了大剂量米托蒽醌和中剂量阿糖胞苷治疗 30例难治性或复发的白血病的效果。米托蒽醌静脉注射总剂量为 4 0mg m2 ,阿糖胞苷剂量为每天 1- 1.5 g m2 ,注射时间为 3小时连续 5天。 2 6例病人获得完全缓解 (缓解率为87% ) ,1例 (3.3% )部分缓解 ,治疗过程中无病例死亡。平均获得完全缓解所需的时间为 30天左右。平均无病生存和存活时间分别为 3.5和 6个月。主要副作用为造血系统受抑。结果显示短程大剂量米托蒽醌联合阿糖胞苷治疗难治性或复发的白血病可获得较高的缓解率 。Although chemotherapy can achieve a high rate of disease remission in patients with newly diagnosed acute leukemia, patients with recurrent or refractory leukemia generally have a poorer rate of response. This study was designed to assess the utility of high-dose mitoxantrone and intermediate-dose cytarabine in the treatment of patients with relapsed or refractory acute leukemia. Thirty patients with relapsed or refractory acute leukemia were treated with mitoxantrone at a total dose of 40 mg/m 2 intravenously and cytarabine 1-1.5 g/m 2 over 3 hours once daily for five doses. Twenty-six of thirty patients achieved complete response (CR 87%) and one achieved partial response (PR 3.3%). No patient died during the induction course. The main toxic effect was hematopoietic suppression that was clinically acceptable. The median time needed for CR was around 30 days. The median disease-free and overall survival times were 3.5 and 6 months, respectively. The results demonstrate that short course high-dose mitoxantrone with cytarabine is associated with a trend toward a higher CR rate and therefore, it should be an effective antileukemic regimen for the treatment of refractory and relapsed acute leukemia.

关 键 词：急性白血病 米托蒽醌 阿糖胞苷 治疗 

分 类 号：R733.710.5[医药卫生—肿瘤]